TOBI tobramycin inhalation product: PGNS completed two Phase III trials of TOBI in 468 patients.

PathoGenesis Corp. (PGNS), Seattle, Wash. Product: TOBI tobramycin inhalation product Indication: Chronic lung infections in cystic fibrosis Status: PGNS completed two Phase III trials of TOBI in 468...